| Project/Area Number |
24500389
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Neuroscience in general
|
|---|
| Research Institution | Himeji Dokkyo University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
MATSUYAMA SHOGO 姫路獨協大学, 薬学部, 教授 (80243319)
TANIGUCHI TAIZO 姫路獨協大学, 薬学部, 教授 (70346253)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
TAKANO MASAOKI 神戸学院大学, 薬学部, 講師 (30258107)
OTANI MIEKO 神戸学院大学, 薬学部, 助教 (40068284)
FUNAKOSHI HIROSHI 旭川医科大学, 医学部, 教授 (40273685)
|
|---|
| Project Period (FY) |
2012-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2012: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | タウオパチー / タウ蛋白 / 学習記憶機能 / 肝細胞増殖因子 / タウ蛋白質 |
|---|
| Outline of Final Research Achievements |
We studied the pathophysiological mechanisms of familial frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17) using transgenic mouse overexpressing mutated human tau at 5, 10, 15 and 20 months of age. We performed proteomic analysis of the hippocampus and cerebral cortex of wild type and FTDP-17 model mice using 2-dimensional gel electrophoresis followed by mass spectrometry to clarify proteins and phosphoproteins involved in impaired learning and memory. We identified some proteins and phosphoproteins to be significantly changed in the hippocampus and cortex of wild type and FTDP-17 model mice. These results suggested that identified proteis and phosphoproteins contributes to the pathophysiology of FTDP-17. Furthermore, we examined therapeutic potential of hepatocyte growth factor (HGF) using double transgenic mice overexpressing mutated human Tau and HGF. Currently, we are considering the possibility that HGF is an effective therapeutic agent against FTDP-17.
|
